Find Academic Supervisors

Martin PeiferView profile

Professor

• Computational Cancer Genomics
• Tumor Evolution
• Genome Instability
• +5 more

Professor Martin Peifer is a computational cancer genomics researcher at the University of Cologne, where he leads the Department of Translational Genomics. He serves as Principal Investigator of the Peifer Lab, which focuses on developing computational methods to analyze cancer genome sequencing data. His work is deeply integrated with the Center for Data and Simulation Science and he is an active member of the International Cancer Genome Consortium and the Pan-Cancer Analysis of Whole Genomes project. Peifer's research interests center on computational approaches to understanding cancer biology, with particular emphasis on tumor evolution and genome instability mechanisms. His lab develops methods to analyze somatic genome alterations including point mutations, copy number changes, and rearrangements. They also create computational tools for integrative genome analyses, tumor evolution reconstruction, and single-cell sequencing data analysis (both RNA and DNA). His interdisciplinary team applies high-performance computing and machine learning to interpret complex cancer sequencing data, aiming to better understand tumorigenesis, clonal evolution, and therapy resistance. Analysis of Peifer's extensive publication record reveals a strong focus on neuroblastoma and lung cancer genomics, with particular attention to tumor evolution patterns and genomic instability mechanisms. His work spans multiple cancer types but maintains consistent themes of computational methodology development and application to understand cancer progression and treatment resistance. The publications demonstrate increasing sophistication in analyzing intra-tumor heterogeneity and clonal dynamics over time. Peifer leads an active research group including postdoctoral fellows (Joel Kaufmann, Dr. Stephanie Pabel, Agnieszka Rumińska) and PhD students (Magdalena Seiffert, Justinas Valiulis). His lab is involved in the Collaborative Research Center 1399 focused on Mechanisms of Drug Sensitivity and Resistance in Small Cell Lung Cancer, indicating significant grant funding and collaborative research efforts. The Peifer Lab operates at the intersection of computational biology and cancer research, maintaining an interdisciplinary approach that combines bioinformatics, machine learning, and high-performance computing to address complex questions in cancer genomics. Their work has significant implications for understanding cancer evolution and developing more effective treatment strategies.

• Bioinformatics
• Systems Biology
• Disease Module Identification
• +6 more

Zelmina Lubovac is a Senior Lecturer in BioInformatics at the School of Bioscience, University of Skövde. She serves as both a Course Coordinator for multiple undergraduate and graduate courses in bioinformatics and a Programme Coordinator for Master's level programs. Her academic work focuses on the intersection of computational methods and biological applications, particularly in disease analysis and biomarker discovery. Dr. Lubovac's research spans several key areas in bioinformatics and systems biology: Disease module identification in complex biological networks Multi-omics integration (genomics, proteomics, metabolomics) for biomarker discovery Machine learning applications in RNA-seq and other high-throughput biological data Development of bioinformatics software tools for network analysis miRNA analysis in cancer and neurological disorders Her recent publications (2022-2024) demonstrate a strong focus on applying computational approaches to understand disease mechanisms, particularly in pancreatic cancer and multiple sclerosis. She has developed several widely-used bioinformatics tools including MODalyseR, MODifieR, and TFTenricher that facilitate disease module analysis and gene network interpretation. Her work often involves collaborative research with clinical teams to translate computational findings into potential diagnostic applications. Dr. Lubovac has been involved in significant research projects including: BIO-AID (Biomedical AI-driven data analytics): Oct 2020 - Sep 2024 Systems Biology DMDPipe: Mar 2018 - Feb 2021 She actively contributes to both undergraduate and graduate education at the University of Skövde, coordinating multiple courses and programs in bioinformatics and bioscience, with a clear emphasis on preparing students for careers at the intersection of biology and computational science.

Hans H. WandallView profile

Professor

• Glycobiology
• Tissue Homeostasis
• Cancer Biology
• +5 more

Hans H. Wandall is Professor and Deputy Head of Department at the University of Copenhagen's Department of Cellular and Molecular Medicine, Faculty of Health Sciences. He serves as Group Leader and Vice-Director of the Copenhagen Center for Glycomics. His educational background includes a PhD in Glycobiology (2004), medical licensure (2001), and MD from University of Copenhagen (1999). Research focuses on glycobiology using gene editing and tissue models to understand glycan functions in: Tissue development and cancer biology Host-virus interactions (HSV-1, Ebola) Stem cell regulation and regenerative medicine Glycan-based therapeutic development Recent publications demonstrate interdisciplinary approaches combining glycoproteomics, virology, and cancer biology, with emphasis on O-glycosylation mechanisms and viral pathogenesis. Awards & Recognition: ERC Consolidator Grant (2017) Lundbeck Foundation Ascending Investigator (2019) Sapere Aude Research Leader Award (2012) Young Scientist Award (2003) Leads multiple funded projects from Lundbeck Foundation, Novo Nordisk Foundation, and Danish National Research Foundation. Supervises doctoral candidates and postdoctoral researchers while directing the GlycoMedicine research group. Founded biotech ventures including GO-Therapeutics and Hemab ApS.

Kelly Fagan RobinsonView profile

Assistant Professor

• Medical Anthropology
• Disability Studies
• Communication Theory
• +6 more

Dr. Kelly Fagan Robinson is an Assistant Professor in Medical Anthropology at the University of Cambridge, affiliated with Clare Hall and the Department of Social Anthropology. Her research examines how social relations, communication practices, and institutional structures create epistemic dissonances that marginalize individuals categorized as disabled, autistic, or migrants. University of Cambridge Clare Hall Department of Social Anthropology Early Cancer Research Institute Her work spans medical anthropology, disability studies, and policy analysis, focusing on the material ecologies of policy failures, communication inequalities in cancer research, and multimodal methodologies rooted in Deaf values. She lectures on non-normal ways of being, multimodal attention techniques, and communication differences. Research Projects: Elusive Risks, Communication Faultlines, Shared Risk - ACED Teaching: Multimodal Communication, Epistemic Justice, Deaf-Centered Methodologies Dr. Robinson holds an NVQ 6 in British Sign Language, emphasizing practical engagement with Deaf communities. Her publications analyze Deaf epistemologies, translanguaging in performance, and institutional barriers to inclusivity.

James LacefieldView profile

Professor

• Biomedical Ultrasound Imaging
• Vascular Imaging
• Cancer Research Applications
• +5 more

James Lacefield is a Professor in both the Department of Electrical and Computer Engineering and the Department of Medical Biophysics at Western University. He serves as Director of the School of Biomedical Engineering and maintains his research laboratory in the Amit Chakma Engineering Building. His academic appointments span multiple disciplines, reflecting the interdisciplinary nature of his work in biomedical ultrasound imaging. Dr. Lacefield earned his Ph.D. and B.S.E. in Biomedical Engineering from Duke University. His educational background established the foundation for his current research program that bridges engineering principles with medical applications. His research focuses on the physical acoustics and signal processing aspects of ultrasound imaging, with particular emphasis on quantitative vascular imaging applications. Dr. Lacefield's laboratory develops novel methods for color Doppler, power Doppler, and contrast-enhanced ultrasound imaging, with primary applications in cancer research. Current projects include optimization of high-resolution ultrasound systems for tumor vascular characterization and development of methods to quantify spatial blood flow distribution in tumors. Analysis of his recent publications reveals a strong focus on quantitative ultrasound techniques for cancer applications, with particular attention to tumor perfusion assessment using contrast-enhanced ultrasound. His work demonstrates increasing sophistication in speckle analysis methods to improve the reliability of perfusion measurements in preclinical tumor models. Associate Editor, IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control Member, Council of Chairs of Bioengineering and Biomedical Engineering Member, College of Reviewers, Canadian Institutes of Health Research Dr. Lacefield maintains active collaborations with multiple research groups including the Imaging Research Laboratories at Robarts Research Institute. His professional activities include editorial work for major ultrasound journals and participation in national review panels for biomedical research funding.

Lori PassmoreView profile

Research Fellow

• Molecular Biology
• Biochemistry
• Structural Biology
• +5 more

Lori Passmore is a Research Fellow at the Medical Research Council Laboratory of Molecular Biology (MRC-LMB), part of the University of Cambridge's School of Clinical Medicine. Her work focuses on understanding the molecular mechanisms of multi-protein complexes involved in gene expression regulation and DNA repair. Studied pre-mRNA 3′-end processing via the Cleavage and Polyadenylation Factor (CPF) complex Investigated DNA crosslink repair through the Fanconi Anemia pathway Developed cryo-EM methodologies for structural analysis Her laboratory employs a hybrid approach combining electron cryo-microscopy , X-ray crystallography, biochemical assays, and genetic techniques to elucidate complex architectures and functional dynamics. Notable discoveries include structural insights into the FANCD2-FANCI complex and mechanisms of poly(A) tail length regulation. Current research spans topics such as: 3′-end processing coordination mRNA deadenylation pathways DNA replication stress responses Protein complex assembly principles Lori Passmore's group includes trainees and staff studying these fundamental biological processes. Their work contributes to understanding gene regulation, RNA metabolism, and DNA repair mechanisms critical for preventing diseases like cancer.

• Microfluidics
• BioMEMS
• Lab-on-a-Chip Technology
• +11 more

Prof. Kwang W. Oh is a tenured Professor at the Department of Electrical Engineering and Department of Biomedical Engineering within the School of Engineering and Applied Sciences at University at Buffalo (SUNY at Buffalo) . He serves as the Director of Graduate Studies in Electrical Engineering and Director of SMALL (Sensors and MicroActuators Learning Lab) . His academic journey includes PhD and MS in Electrical and Computer Engineering from University of Cincinnati (2001, 1997) and BS in Physics from Chonbuk National University (1995). Prof. Oh's research expertise lies at the intersection of microfluidics , BioMEMS , and lab-on-a-chip technologies. His lab has pioneered vacuum-driven microfluidic devices , PDMS-based systems , droplet manipulation , and chemical-free fabrication techniques . His work enables point-of-care diagnostics , single cell analysis , and wearable medical sensors , with significant contributions to sample-to-answer nanosystems and world-to-chip interfacing . The scientific awards section highlights his excellence in teaching and research: SUNY Chancellor's Award for Excellence in Teaching (2020) Meyerson Award for Undergraduate Teaching (2019) Qualcomm Faculty Award (2019) Senior Teacher of the Year (2017) Royal Society of Chemistry's Emerging Investigators (2013) Samsung Electronics' CEO Honor (2003) His lab has produced numerous PhD and MS students including Dr. Anyang Wang (2020), Dr. Nikhila Nyayapathi (2020), Mr. Liam Christie (2021), and Dr. Domin Koh (2019). As a conference chair , he has organized symposia at NanoTech (2012-2026) and served as editorial board member for Sensors , Micromachines , and Biomedical Engineering Letters .

Feyruz V. RassoolView profile

Professor

• DNA damage and repair
• Genomic instability
• Epigenetic therapy
• +7 more

Feyruz V. Rassool is a Professor at the University of Maryland School of Medicine, with primary appointment in Radiation Oncology. She serves as Co-director of the Experimental Therapeutics Program at the University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC) and holds an adjunct Associate Professor position at VARI’s Center for Epigenetics. Her research focuses on DNA damage/repair pathways in cancer, particularly their therapeutic exploitation through PARP and DNMT inhibitors. Education: B.Sc. in Human Genetics (1983, University College London), Ph.D. in Biological Sciences (1990, Royal Postgraduate Medical School) Postdoctoral Training: University of Chicago (1990-1994) Her work explores the intersection of DNA repair , epigenetics , and mitochondrial dysfunction to develop novel therapies for breast, ovarian, lung, and leukemias. Key projects include STING-dependent interferon signaling , pathogen mimicry in cancer cells, and metastasis suppression through PARPi/epigenetic combinations. Dr. Rassool is part of the SU2C Epigenetics Dream Team and has secured multiple grants from NCI, NIH, and the Adelson Medical Research Foundation. Her recent preclinical studies with PARP/DNMT inhibitors are being translated into Phase I/II trials for AML and TNBC. Scientific Awards Ziskin Award (2012) NCI-SPORE Grant Co-Leader NIH/NCI P30 CA134274 Support Grant She has mentored 13 PhD/postgraduate researchers and collaborates on clinical trials with Pfizer, VARI-SU2C, and ASTRO. Her lab employs techniques like DNA repair assays , RNAseq , and mouse xenograft models to investigate mechanisms of action for epigenetic drugs.

Stephan A. SieberView profile

Professor

• Bioorganic Chemistry
• Antibiotic Development
• Chemical Proteomics
• +5 more

Professor Stephan A. Sieber is a leading researcher in bioorganic chemistry at the Technical University of Munich (TUM), where he holds the Chair of Organic Chemistry II within the TUM School of Natural Sciences. His research program focuses on developing new drugs against multidrug-resistant bacteria through a multi-disciplinary approach that integrates synthetic chemistry, functional proteomics, microbiology, and protein biochemistry. His laboratory has made significant contributions to identifying unprecedented antibacterial targets beyond the scope of current antibiotics and exploiting these for chemical manipulation. Recent work has increasingly incorporated machine learning approaches to accelerate antibiotic discovery, with notable publications on AI-guided pipelines, drug-target interaction prediction, and high-throughput screening optimization. Sieber's research has resulted in the discovery of new active substances, some of which are currently being optimized for medical applications. His group's publications reveal a strong focus on chemical proteome mining, natural product mode of action studies, and novel antibacterial target identification. The lab has published extensively in top journals including Nature Chemistry, Nature Communications, and ACS Central Science. Inhoffen Medal (2024) Max Bergmann Medal (2023) ERC Advanced Grant (2023) Merck Future Insight Prize (2020) Klaus Grohe Prize (2020) ERC Consolidator Grant (2016) Professor Sieber leads an active research group that maintains a strong presence in the scientific community through regular publications, conference presentations, and collaborations. His laboratory website and BlueSky presence (@sieberlab.bsky.social) demonstrate ongoing research activities and engagement with the broader scientific community. He has successfully secured significant research funding including multiple ERC grants that have supported his innovative work in antibiotic discovery.

• Extracellular Vesicles
• Biomarker Discovery
• Exosome Biology
• +7 more

Carlos Salomon Gallo is a Professor and NHMRC Investigator Fellow (EL2) at The University of Queensland's Centre for Clinical Research, affiliated with the School of Biomedical Sciences. He directs the Centre for Extracellular Vesicle Nanomedicine and leads the Exosome Biology Laboratory. A globally recognized key opinion leader in extracellular vesicles (ranked 3rd worldwide by Expertscape), his research focuses on EV biology for diagnostic and therapeutic applications in ovarian cancer, gestational diabetes, preeclampsia, and other obstetrical syndromes. His research integrates proteomics (SWATH-MS), miRNA analysis, and advanced isolation techniques to develop liquid biopsies. Core interests include: EV biomarker discovery and validation for early disease detection. Mechanisms of EV-mediated signaling in metabolic and oncological pathologies. Engineering EVs for targeted drug delivery and CRISPR-Cas therapeutics. Clinical translation of EV-based diagnostics (IVDs) and therapeutics. Analysis of his recent articles reveals a dominant focus on EV profiling in pregnancy complications (gestational diabetes, preeclampsia) and oncology (ovarian cancer), utilizing multi-omics approaches. Key trends include developing high-sensitivity EV biosensors, understanding hypoxia-induced EV signaling, and exploring 3D models for EV research. He has received significant recognition, including: NHMRC Emerging Leadership Fellow NHMRC Investigator Fellow (EL2) He leads the Exosome Biology Laboratory and the UQ Centre for Extracellular Vesicle Nanomedicine, fostering cross-disciplinary collaboration. His work involves extensive national and international partnerships, evidenced by leadership roles in the Centre for Clinical Diagnostics and over 20 invited international talks in 5 years. He actively mentors HDR students and contributes to global EV research standards (MISEV2023).

• Neuro-oncology
• Neuropathology
• Glioblastoma
• +3 more

Professor Patrick Harter is a faculty member at the Institute of Neuropathology, Ludwig Maximilian University of Munich (LMU), where he leads research in neuro-oncology and molecular diagnostics of CNS tumors. His work focuses on glioblastoma, meningioma, and brain metastasis, with emphasis on epigenetic mechanisms like DNA methylation and metabolic adaptations in the tumor microenvironment. Research interests span: Molecular classification of brain tumors using DNA methylation profiling Therapeutic targeting of BRAF/MEK and PI3K/Akt/mTOR pathways Role of hypoxia and metabolic plasticity in treatment resistance Liquid biopsy development for non-invasive tumor monitoring His recent publications demonstrate a strong trend toward integrating epigenetic, metabolic, and immunotherapeutic approaches. Articles frequently explore: Novel biomarkers for tumor grading and prognosis Mechanisms of therapy resistance in gliomas Impact of tumor microenvironment on metastasis

Olga G. TroyanskayaView profile

Professor

• Bioinformatics
• Computational Genomics
• Machine Learning in Biology
• +6 more

Olga G. Troyanskaya is a Professor of Computer Science and the Lewis-Sigler Institute for Integrative Genomics at Princeton University. She serves as Deputy Director for Genomics at the Simons Center for Data Analysis, Simons Foundation, NYC. Her research focuses on computational biology, integrating diverse high-throughput genomic datasets to model molecular pathways in health and disease. Professor of Computer Science and Lewis-Sigler Institute for Integrative Genomics Deputy Director for Genomics, Simons Center for Data Analysis Research Interests: Troyanskaya’s work addresses challenges in bioinformatics, including algorithm development for gene expression analysis, regulatory network modeling, and disease mechanism interpretation. She combines computational methods with experimental validation using S. cerevisiae as a model organism. Scientific Trends: Recent publications emphasize single-cell multiomics, deep learning for transcriptional regulation, cancer immunotherapy design, and epigenomic analysis of immune responses. Key themes include computational modeling of genetic networks, disease-specific pathway analysis, and high-resolution omics frameworks. Collaborative roles in autism, Alzheimer’s, kidney disease, and cancer research Developed tools like HumanBase for data-driven predictions

• Applied Mathematics
• Mathematical Biology
• Computational Biology
• +4 more

Ruth Baker is a Professor of Applied Mathematics at the University of Oxford and a key member of the Mathematical Institute . Her work bridges mathematics, computational modeling, and biology to address complex developmental systems. Research Interests : Developing mathematical frameworks for cell and tissue-level biological processes Integrating computational and statistical methodologies with experimental data Exploring data-driven modeling for multidisciplinary collaboration Scientific Awards : Simons Investigator (2024-2029) Royal Society Wolfson Research Merit Award (2017-2022) FIMA (2021) FRSB (2020) Leverhulme Research Fellowship (2017-2019) London Mathematical Society Whitehead Prize (2014)

• Epidemiologic Factors
• Epidemiologic Methods
• Glioblastoma
• +7 more

Katsuhito Yasuno is a Research Scientist in the Department of Neurosurgery at Yale School of Medicine. He works within the Gunel Lab, focusing on neurogenetic research related to brain disorders, vascular conditions, and tumors. His work involves genomic analyses and molecular studies to understand the genetic basis of various neurological conditions. Education: Postdoctoral Fellow, Japan Science and Technology Corporation (2008) Postdoctoral Fellow, Japan Biological Informatics Consortium (2006) Postdoctoral Fellow, Tokai University School of Medicine (2004) PhD in Theoretical Physics, Tokyo Institute of Technology (2002) MS in Theoretical Physics, Tokyo Institute of Technology (1999) BS in Physics, Tokyo Metropolitan University (1997) Dr. Yasuno's research spans multiple areas of neurogenetics and molecular neuroscience. His primary interests include epidemiologic factors and methods related to brain tumors (particularly glioblastoma and meningioma), intracranial aneurysms, nervous system diseases and malformations, and vascular diseases. His physics background contributes to sophisticated analytical approaches in genetic research. His publication record shows consistent contributions to understanding the genetic mechanisms underlying neurological disorders, with recent work focusing on meningioma genetics, brain malformations, and vascular disorders. The research demonstrates a progression from basic genetic discovery to translational applications, with particular emphasis on molecular pathways that could serve as therapeutic targets. Dr. Yasuno collaborates extensively with leading researchers in the field, most notably with Dr. Murat Günel (28 common publications) and Dr. Kaya Bilguvar (34 common publications). His work involves both computational analysis and laboratory validation of genetic findings. As part of the Gunel Lab, Dr. Yasuno contributes to the lab's three major research interests: developmental neurogenetic disorders, neurovascular disorders, and brain tumor biology. The lab utilizes advanced genomics techniques and bioinformatic analysis for gene discovery followed by functional studies.

Olga KovalchukView profile

Professor

• Epigenetics
• Cancer Biology
• Radiation Biology
• +5 more

Olga Kovalchuk is a Professor in the Department of Biological Sciences at the University of Lethbridge. She leads the Epigenetics of Health and Disease research laboratory, which is affiliated with the Southern Alberta Cancer Research Institute (SACRI) and Alberta Health Services/Alberta Cancer Foundation (AHS/ACF). Her research program has received significant funding including a $3.2 million Canada Foundation for Innovation (CFI) start-up grant and NSERC Discovery Grants. Dr. Kovalchuk's research focuses on the role of epigenetic mechanisms in health and disease, particularly in the context of radiation exposure and cancer. Her primary areas of investigation include epigenetic dysregulation in carcinogenesis, radiation epigenetics, DNA damage and repair mechanisms, and transgenerational effects of radiation exposure. She has made significant contributions to understanding how radiation-induced epigenetic changes affect genome stability, cancer development, and treatment responses. Analysis of her recent publications reveals a strong focus on microRNA regulation in cancer, sex-specific radiation responses, and the epigenetic basis of radiation-induced bystander effects. Her work demonstrates how epigenetic changes, particularly DNA methylation and microRNA expression patterns, mediate radiation responses in various tissues and can be transmitted across generations. Much of her research utilizes mouse models to investigate these mechanisms in vivo. Board of Governors Research Chair at University of Lethbridge CIHR Institute of Gender and Health Research Chair in New Perspectives in Gender, Sex and Health Canada Foundation for Innovation Start-up Funding ($3.2 Million) NSERC Discovery Grant recipient Editor's Choice Paper Award for research on radiation-induced bystander effects Cover Page feature for transgenerational radiation effects research Dr. Kovalchuk actively mentors numerous graduate students and postdoctoral fellows, with a research team comprising PhD students, MSc students, research assistants, and postdoctoral associates. Her laboratory collaborates extensively with researchers at MIT, Harvard University, and other institutions. She has secured significant grant funding including NSERC Discovery Grants and CFI start-up funds to support her research program investigating epigenetic mechanisms in radiation biology and cancer. Her laboratory, the Epigenetics of Health and Disease research group, maintains strong collaborations with the Southern Alberta Cancer Research Institute and has established partnerships with researchers across North America. Dr. Kovalchuk's work has important implications for understanding radiation risks, improving cancer therapies, and developing strategies to mitigate radiation damage.